Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0021 Transporter Info
Gene Name SLC15A1
Transporter Name Peptide transporter 1
Gene ID
6564
UniProt ID
P46059
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Valacyclovir

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valacyclovir inhibits the transportation of Cefadroxil by SLC15A1 (Ki = 910 microM) [1]

Affected Drug/Substrate

 Cefadroxil Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  DT Modulation 2

 Valacyclovir inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 1280 microM) [1]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  DT Modulation 3

 Valacyclovir inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 4080 microM) [3]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Oocytes-PEPT1

  DT Modulation 4

 Valacyclovir inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 400 microM) [6]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  Cefixime

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefixime inhibits the transportation of Cefadroxil by SLC15A1 (Ki = 1310 microM) [2]

Affected Drug/Substrate

 Cefadroxil Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cefixime inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 10000 microM) [5]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 3

 Cefixime inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 12000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 4

 Cefixime inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cyclacillin

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 600 microM) [4]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 350 microM) [4]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT1

  DT Modulation 3

 Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 500 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 4

 Cyclacillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Ceftibuten

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ceftibuten inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 870 microM) [5]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Ceftibuten inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 710 microM) [5]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT1

  DT Modulation 3

 Ceftibuten inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 340 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 4

 Ceftibuten inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Ampicillin

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ampicillin inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 10000 microM) [9]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  DT Modulation 2

 Ampicillin inhibits the transportation of Valacyclovir by SLC15A1 [1]

Affected Drug/Substrate

 Valacyclovir Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  DT Modulation 3

 Ampicillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefuroxime

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefuroxime inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 26000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cefuroxime inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki > 5000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 3

 Cefuroxime inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Losartan

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Losartan inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 52 microM) [10]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT1

  DT Modulation 2

 Losartan inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 24 microM) [10]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Valsartan

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valsartan inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 560 microM) [10]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT1

  DT Modulation 2

 Valsartan inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 390 microM) [10]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefamandole

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefamandole inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 8100 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cefamandole inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefmetazole

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefmetazole inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 28000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cefmetazole inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cephapirin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephapirin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki > 10000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cephapirin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cephradine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephradine inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 9.8 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cephradine inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cloxacillin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cloxacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 3000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Cloxacillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Dicloxacillin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dicloxacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 7200 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Dicloxacillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Moxalactam

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Moxalactam inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 12300 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Moxalactam inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Oxacillin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oxacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 12000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Oxacillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefadroxil

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefadroxil inhibits the transportation of Glycylsarcosine by SLC15A1 [11]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT1

  DT Modulation 2

 Cefadroxil inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Irbesartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Irbesartan inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 230 microM) [10]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Levodopa

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Levodopa inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 141200 microM) [12]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  Methyldopa

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyldopa inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 151600 microM) [12]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT1

  Fosinopril

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fosinopril inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 35.5 microM) [13]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefsulodin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefsulodin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki > 30000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Ceftazidime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ceftazidime inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki > 10000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Bestatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bestatin inhibits the transporation of melatonin by SLC15A1 (IC50 = 1000 microM) [14]

Affected Drug/Substrate

 Melatonin Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)

  Loracarbef

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Loracarbef inhibits the transportation of Cefadroxil by SLC15A1 [2]

Affected Drug/Substrate

 Cefadroxil Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefdinir

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefdinir inhibits the transportation of Glycylsarcosine by SLC15A1 [5]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT1

  Captopril

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Captopril inhibits the transportation of Sulpiride by SLC15A1 [15]

Affected Drug/Substrate

 Sulpiride Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefaclor

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefaclor inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefazolin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefazolin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefepime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefepime inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefotaxime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefotaxime inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefoxitin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefoxitin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cefpodoxime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefpodoxime inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Ceftriaxone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ceftriaxone inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cephalexin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephalexin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Cephalothin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephalothin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Floxacillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Flucloxacillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Penicillin V

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Penicillin V inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Piperacillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Piperacillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Azathioprine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Azathioprine inhibits the expression of SLC15A1 [16]

  Arsenic Trioxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Arsenic Trioxide inhibits the expression of SLC15A1 [17]

  Fluvastatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluvastatin inhibits the activity of SLC15A1 [18]

  Repaglinide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Repaglinide inhibits the activity of SLC15A1 [18]

  Fluorouracil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluorouracil inhibits the expression of SLC15A1 [19]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the expression of SLC15A1 [20]

  Isotretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Isotretinoin inhibits the expression of SLC15A1 [21]

  Metformin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metformin increases the expression of SLC15A1 [22]

  Zoledronic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zoledronic Acid increases the expression of SLC15A1 [23]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid affects the expression of SLC15A1 [24]

  Liothyronine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Liothyronine inhibits the expression of SLC15A1 [25]

  Rifampin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifampin inhibits the expression of SLC15A1 [26]

  Urethane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Urethane inhibits the expression of SLC15A1 [27]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the expression of SLC15A1 [28]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin induces the activity of SLC15A1 [19]

  Quinapril

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinapril inhibits the activity of SLC15A1 [29]

  Insulin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Insulin induces the activity of SLC15A1 [30]

  Enalapril

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Enalapril inhibits the activity of SLC15A1 [31]

Drug in Phase 3 Trial

  Benzylpenicillin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzylpenicillin inhibits the transportation of Glycylsarcosine by SLC15A1 (Ki = 30000 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  DT Modulation 2

 Benzylpenicillin inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

  Resveratrol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Resveratrol increases the expression of SLC15A1 [32]

Regulation Mechanism

 via enhancement of Nuclear factor erythroid 2-related factor 2 (NFE2L2) Transcription Factor Info

Cell System

 Human colon adenocarcinoma cells (Caco-2)

Drug in Phase 2 Trial

  MeIQx

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MeIQx inhibits the expression of SLC15A1 [35]

Drug in Phase 1 Trial

  Aspartame

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aspartame inhibits the activity of SLC15A1 [18]

  AICA ribonucleotide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 AICA ribonucleotide inhibits the activity of SLC15A1 [22]

Discontinued Drug

  MDL-28170

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MDL-28170 inhibits the activity of SLC15A1 [8]

Cell System

 Human enterocyte-like 2 cell (Caco-2)-PEPT1

Investigative Drug

  Milchsaure

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Milchsaure inhibits the expression of SLC15A1 [36]

  4-AMBA

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-AMBA inhibits the activity of SLC15A1 [39] , [40]

  [11C]GlySar

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 [11C]GlySar modulates the activity of SLC15A1 [41]

  [14C]GlySar

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 [14C]GlySar modulates the activity of SLC15A1 [41]

  [3H]GlySar

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 [3H]GlySar modulates the activity of SLC15A1 [41]

Natural Product

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyleugenol inhibits the expression of SLC15A1 [37]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution affects the expression of SLC15A1 [38]

Environmental toxicant

  Zinc

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zinc inhibits the activity of SLC15A1 [33]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 affects the expression of SLC15A1 [20]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC15A1 [37]

Health and Environmental Toxicant

  Pirinixic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pirinixic acid increases the expression of SLC15A1 [34]
References
1 Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54.
2 Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9.
3 Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun. 1998 Sep 18;250(2):246-51.
4 Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7.
5 Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308.
6 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998 Aug;15(8):1154-9.
7 Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.
8 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
9 Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res. 1996 Nov;13(11):1631-4.
10 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
11 Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem. 1995 Mar 24;270(12):6456-63.
12 CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50.
13 Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab Dispos. 2001 Oct;29(10):1307-15.
14 Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: An implication of the therapeutic potential. J Pineal Res. 2017 May;62(4).
15 Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Jul;25(7):885-90.
16 Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology. 2003 Jun;124(7):1950-7.
17 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
18 In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res. 2005 Apr;22(4):512-7.
19 Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett. 2005 Dec 8;230(1):72-80.
20 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
21 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
22 Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter. Mol Pharmacol. 2012 Mar;81(3):319-27.
23 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
24 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
25 Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. Int J Pharm. 2015 Nov 10;495(1):588-598.
26 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
27 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
28 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
29 Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2. Pharm Res. 2000 May;17(5):526-32.
30 Role of insulin on jejunal PepT1 expression and function regulation in diabetic male and female rats. Can J Physiol Pharmacol. 2010 Jul;88(7):753-9.
31 The apical uptake transporter of levofloxacin is distinct from the peptide transporter in human intestinal epithelial Caco-2 cells. Drug Metab Pharmacokinet. 2008;23(5):373-8.
32 Nrf2 regulates the expression of the peptide transporter PEPT1 in the human colon carcinoma cell line Caco-2. Biochim Biophys Acta. 2014 Jun;1840(6):1747-54.
33 Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2. Pharm Res. 2003 Sep;20(9):1389-93.
34 Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha. Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G851-6.
35 Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. Toxicol Appl Pharmacol. 2010 Nov 15;249(1):91-100.
36 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
37 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
38 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
39 Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther. 2010 Jan;332(1):220-8.
40 Activation of vagal afferents in the rat duodenum by protein digests requires PepT1. J Nutr. 2005 Jun;135(6):1491-5.
41 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984).

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.